ASO Visual Abstract: Real-World Implications of the SOUND Trial

Andreas Giannakou; Olga Kantor; Ko Un Park; Adrienne G Waks; Rinaa S Punglia; Laura S Dominici; Faina Nakhlis; Elizabeth A Mittendorf; Tari A King

doi:10.1245/s10434-024-16465-5

ASO Visual Abstract: Real-World Implications of the SOUND Trial

Ann Surg Oncol. 2025 Jan;32(1):121-122. doi: 10.1245/s10434-024-16465-5.

Authors

Andreas Giannakou^{1

2

3}, Olga Kantor^{1

2

3}, Ko Un Park^{1

2

3}, Adrienne G Waks^{2

3

4}, Rinaa S Punglia^{2

3

5}, Laura S Dominici^{1

2

3}, Faina Nakhlis^{1

2

3}, Elizabeth A Mittendorf^{1

2

3}, Tari A King^{6

7

8}

Affiliations

¹ Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
³ Harvard Medical School, Boston, MA, USA.
⁴ Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁵ Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁶ Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. tking7@bwh.harvard.edu.
⁷ Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. tking7@bwh.harvard.edu.
⁸ Harvard Medical School, Boston, MA, USA. tking7@bwh.harvard.edu.

PMID: 39521738
DOI: 10.1245/s10434-024-16465-5

Abstract

Nodal disease burden and oncologic outcomes of 312 real-world patients with HR+HER2-breast cancer meeting SOUND eligibility criteria were similar to the SLNB arm of the SOUND trial, supporting careful implementation of omission of SLNB in this population ( https://doi.org/ https://doi.org/10.1245/s10434-024-16354-x ).

MeSH terms

Breast Neoplasms*
Female
Humans
Middle Aged
Prognosis
Receptor, ErbB-2 / metabolism
Receptors, Estrogen / metabolism
Receptors, Progesterone / metabolism
Sentinel Lymph Node Biopsy
Survival Rate

Substances

Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
ERBB2 protein, human